Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune ...

Every winter, respiratory syncytial virus sends tens of thousands of U.S. infants to the hospital, filling pediatric ICU beds ...

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed ...

March 31 (Reuters) - Biotech firm Infinimmune said on Tuesday it has entered into a deal with Merck, that could be worth up ...

Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory ...

Get unlimited access to ad-free articles and exclusive content. The chemotherapy-antibody combinations, known as antibody drug conjugates, have been described as both heat-seeking missiles and Trojan ...

Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million ...

Almost 100% of patients with recurrent/metastatic endometrial cancer benefited from an investigational bispecific antibody ...

New findings reveal that obesity significantly impaired the quality and longevity of antibody responses to a Pseudomonas ...

C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.

Antibody therapeutics are laboratory-made proteins designed to work like the body's natural antibodies. They are widely used ...